Traders purchased shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on weakness during trading hours on Wednesday. $48.48 million flowed into the stock on the tick-up and $35.59 million flowed out of the stock on the tick-down, for a money net flow of $12.89 million into the stock. Of all companies tracked, Alexion Pharmaceuticals had the 8th highest net in-flow for the day. Alexion Pharmaceuticals traded down ($1.37) for the day and closed at $130.36

A number of research analysts recently issued reports on ALXN shares. Leerink Swann reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a report on Friday, June 17th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $185.00 price target on shares of Alexion Pharmaceuticals in a report on Tuesday, August 16th. Jefferies Group reaffirmed a “hold” rating on shares of Alexion Pharmaceuticals in a report on Sunday, May 29th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating and issued a $221.00 price target (down from $228.00) on shares of Alexion Pharmaceuticals in a report on Tuesday, June 7th. Finally, SunTrust Banks Inc. cut their price target on Alexion Pharmaceuticals from $220.00 to $197.00 and set a “buy” rating for the company in a report on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $182.85.

The company’s 50 day moving average is $131.16 and its 200-day moving average is $135.82. The stock has a market cap of $29.23 billion, a PE ratio of 327.54 and a beta of 1.08.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/investors-buy-shares-of-alexion-pharmaceuticals-inc-alxn-on-weakness.html

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing the consensus estimate of $1.17 by $0.04. The firm earned $753 million during the quarter, compared to the consensus estimate of $743.18 million. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. Alexion Pharmaceuticals’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.44 earnings per share. On average, equities analysts expect that Alexion Pharmaceuticals Inc. will post $4.65 earnings per share for the current fiscal year.

In other news, CEO David Hallal sold 332 shares of the firm’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $137.14, for a total transaction of $45,530.48. Following the completion of the transaction, the chief executive officer now directly owns 189,266 shares in the company, valued at $25,955,939.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Vikas Sinha sold 277 shares of the firm’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $37,987.78. Following the transaction, the chief financial officer now owns 178,463 shares of the company’s stock, valued at $24,474,415.82. The disclosure for this sale can be found here. Insiders own 4.41% of the company’s stock.

Institutional investors have recently modified their holdings of the company. FMR LLC increased its position in shares of Alexion Pharmaceuticals by 12.0% in the second quarter. FMR LLC now owns 18,745,795 shares of the biopharmaceutical company’s stock worth $2,188,759,000 after buying an additional 2,002,085 shares during the period. TIAA CREF Investment Management LLC increased its position in shares of Alexion Pharmaceuticals by 34.8% in the second quarter. TIAA CREF Investment Management LLC now owns 2,952,205 shares of the biopharmaceutical company’s stock worth $344,699,000 after buying an additional 762,010 shares during the period. Ameriprise Financial Inc. increased its position in shares of Alexion Pharmaceuticals by 13.7% in the second quarter. Ameriprise Financial Inc. now owns 6,025,775 shares of the biopharmaceutical company’s stock worth $703,575,000 after buying an additional 728,182 shares during the period. Thrivent Financial for Lutherans increased its position in shares of Alexion Pharmaceuticals by 9,454.4% in the second quarter. Thrivent Financial for Lutherans now owns 624,860 shares of the biopharmaceutical company’s stock worth $72,958,000 after buying an additional 618,320 shares during the period. Finally, Brown Advisory Inc. increased its position in shares of Alexion Pharmaceuticals by 23.6% in the second quarter. Brown Advisory Inc. now owns 3,047,631 shares of the biopharmaceutical company’s stock worth $355,841,000 after buying an additional 581,703 shares during the period. Institutional investors own 96.34% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.